Physician profile
Jonathan Pinto
NPI 1245662766
$810.63
in general payments reported to CMS, 2019-2025
9 companies · $18.67 in 2025
The $18.67 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.07 · 2021: $349 · 2022: $189 · 2023: $160 · 2024: $34.95 · 2025: $18.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $217.57 | 2021-2023 | Zeposia |
| Abbvie INC. | $168.68 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.71 | 2021-2023 | Plenvu, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $137.38 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $40.50 | 2020 | |
| Ferring Pharmaceuticals INC. | $33.54 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $18.19 | 2024 | Dupixent |
| Lilly USA, LLC | $16.76 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $16.30 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.